Cornerstone Pharmaceuticals, a privately held pharmaceutical company, has started dosing patients in a recently approved safety and early efficacy clinical trial of CPI-613, its first-in-class altered energy metabolism-directed compound being evaluated for potential use in a wide array of cancers.

Cornerstone Pharmaceuticals has received clearance from the FDA to begin a Phase I/II clinical trial evaluating the safety and early efficacy of its first-in-class altered energy metabolism-directed compound, CPI-613, in a variety of cancer types.